

Review of: "Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels"

Marek Pawlikowski

Potential competing interests: The author(s) declared that no potential competing interests exist.

It is a large and excellent study evaluating the effects of melatonin (MLT) and melatonin-derived drugs on the SARS-CoV-2 entry into the brain and the virus-induced cerebral vessels damage during the experimental model of Covid-19. The study was performed on the K-18 hACE2 mouse model, which expresses the human ACE2 protein. It is well-known that ACE2, an enzyme involved in the degradation of angiotensin II, is also the entry receptor of SARS-CoV-2. Studying this animal model of Covid-19 infection, it was shown that administration of MLT and melatonin-derived drugs (agomelatine and ramelteon) improved the scores of the infection clinical course. The viral load was detected in 100% of the vehicle-treated specimens while the treatment with higher dose of MLT (50 mg) significantly diminished cortical viral load. Interestingly, the viral load is not diminished by the applied drugs in lungs. The possible explanation is that in the case of lungs, the virus invasion is too massive to be counter-acted by MLT and MLT-derived substances. In cerebral cortical samples of SARS-CoV-2-infected mice, higher dose of MLT (50 mg), and to some degree also the other drugs applied, decreased the virus-induced mRNA of the inflammation-linked cytokines, TNF, IL-1 β , and IL-6. It is also found, that MLT and MLT-derived drugs prevent the rarefaction of cerebral cortical blood vessels and suppress the formation of so-called „string vessels“, characteristic for the blood vessels that die. The further investigations showed that MLT, specially at high dose directly interferes with ACE2-dependent SARS-CoV-2 entry into the brain. Numerous previous studies suggested that melatonin may be an adjuvant drug useful in the acute phase of Covid-19 infection. The present paper shows the possible usefulness in protecting the late phase of the Covid-19 disease, connected with the viral brain invasion. The further clinical studies on the prevention and/or treatment of the prolonged post-Covid-19 symptoms are urgently needed.